
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BSLN | Switzerland | CHF | Delayed | |
BSLNz | BATS Europe | CHF | Delayed |
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Nicole Onetto | 72 | 2017 | Independent Non-Executive Director |
Alf Gunnar Martin Nicklasson | 70 | 2013 | Independent Non-Executive Director |
Thomas M. Werner | 69 | 2011 | Independent Vice-Chairman |
Leonard Kruimer | 67 | 2022 | Independent Non-Executive Director |
Carole A. Sable | 63 | 2023 | Independent Non-Executive Director |
Stephan Schindler | - | 2025 | Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review